{"id":388993,"date":"2020-11-27T07:00:17","date_gmt":"2020-11-27T12:00:17","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=388993"},"modified":"2020-11-27T07:00:17","modified_gmt":"2020-11-27T12:00:17","slug":"bioinvent-strengthens-investor-relations","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/bioinvent-strengthens-investor-relations\/","title":{"rendered":"BioInvent strengthens Investor Relations"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">LUND, Sweden<\/span>, <span class=\"xn-chron\">Nov. 27, 2020<\/span> \/PRNewswire\/ &#8212; BioInvent International AB (&#8220;BioInvent&#8221;) (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, announced today the appointment of <span class=\"xn-person\">Cecilia Hofvander<\/span> as Senior Director Investor Relations, a new position at BioInvent covering external communications and investor relations. She will take office within three months and report directly to CEO <span class=\"xn-person\">Martin Welschof<\/span>.<\/p>\n<p>Cecilia has broad experience within investor relations from positions within publicly listed companies in the biotech industry, including Active Biotech, Abliva and most recently at Alligator Bioscience. She holds a B.Sc in Chemistry and Molecular Biology from <span class=\"xn-location\">Lund<\/span> University and has completed the Communication Executive Program at the <span class=\"xn-org\">Stockholm School of Economics<\/span>. Apart from IR and Communication, <span class=\"xn-person\">Cecilia Hofvander&#8217;s<\/span> experience includes business development and international clinical drug trials. \u00a0<\/p>\n<p>&#8220;We are pleased to recruit Cecilia to the BioInvent team,&#8221; said Martin Welschof, CEO of BioInvent. &#8220;She has broad experience from both investor relations and from the science field, a welcome addition to our team as BioInvent advances its position within the immune therapy area and builds international relationships.&#8221;<\/p>\n<p>&#8220;I am delighted of the opportunity to join BioInvent and to be part of its exciting journey. BioInvent has an expanding clinical portfolio within immuno-oncology, an area which over the past decade has emerged as a novel and important approach to cancer treatment,&#8221; said <span class=\"xn-person\">Cecilia Hofvander<\/span>. &#8220;I look forward to joining Martin and his team to contribute further to communication openness and clarity as a means of building long-term relationships with the company&#8217;s stakeholders.&#8221;<\/p>\n<p>About BioInvent <\/p>\n<p \/>\n<p>BioInvent International AB (OMXS: BINV) is a clinical stage company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapies, with two ongoing programs in Phase l\/ll clinical trials for the treatment of hematological cancer and solid tumors, respectively. Two preclinical programs in solid tumors are expected to have entered clinical trials by the end of 2020. The Company&#8217;s validated, proprietary F.I.R.S.T\u2122 technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company&#8217;s own clinical development pipeline or for additional licensing and partnering.The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company&#8217;s fully integrated manufacturing unit. More information is available at <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2994678-1&amp;h=564519377&amp;u=http%3A%2F%2Fwww.bioinvent.com%2F&amp;a=www.bioinvent.com\" rel=\"nofollow noopener noreferrer\">www.bioinvent.com<\/a>.<\/p>\n<p \/>\n<p><b>For further information, please contact:<\/b><\/p>\n<div>\n<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" class=\"prntblns\">\n<tr>\n<td class=\"prngen3\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">Martin Welschof, CEO<\/span><\/p>\n<\/td>\n<td class=\"prngen3\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">Mary-Ann Chang, LifeSci Advisors<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen4\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">+46 (0)46 286 85 50<\/span><\/p>\n<\/td>\n<td class=\"prngen4\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">+44 7483 284 853<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen3\">\n<p class=\"prnews_p\"><span class=\"prnews_span\"><a target=\"_blank\" href=\"mailto:martin.welschof@bioinvent.com\" class=\"prnews_a\" rel=\"nofollow noopener noreferrer\">martin.welschof@bioinvent.com<\/a><\/span><\/p>\n<\/td>\n<td class=\"prngen3\">\n<p class=\"prnews_p\"><span class=\"prnews_span\"><a target=\"_blank\" href=\"mailto:mchang@lifesciadvisors.com\" class=\"prnews_a\" rel=\"nofollow noopener noreferrer\">mchang@lifesciadvisors.com<\/a><\/span><\/p>\n<\/td>\n<\/tr>\n<\/table>\n<\/div>\n<p>BioInvent International AB (publ) <\/p>\n<p \/>\n<p>Co. Reg. No. Org nr: 556537-7263<br \/>Visiting address: Ideongatan 1<br \/>Mailing address: 223 70 LUND<br \/>Phone: +46 (0)46 286 85 50<br \/><a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2994678-1&amp;h=564519377&amp;u=http%3A%2F%2Fwww.bioinvent.com%2F&amp;a=www.bioinvent.com\" rel=\"nofollow noopener noreferrer\">www.bioinvent.com<\/a><\/p>\n<p \/>\n<p><i>The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.<\/i><\/p>\n<p>This information was brought to you by Cision <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2994678-1&amp;h=3690403611&amp;u=http%3A%2F%2Fnews.cision.com%2F&amp;a=http%3A%2F%2Fnews.cision.com\" rel=\"nofollow noopener noreferrer\">http:\/\/news.cision.com<\/a><\/p>\n<p>The following files are available for download:<\/p>\n<div>\n<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" class=\"prnsbt1 prnsbr1 prnsbb1 prnsbl1\">\n<tr>\n<td class=\"prngen3\">\n<p class=\"prnews_p\"><span class=\"prnews_span\"><a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2994678-1&amp;h=235000373&amp;u=https%3A%2F%2Fmb.cision.com%2FMain%2F583%2F3244776%2F1340778.pdf&amp;a=https%3A%2F%2Fmb.cision.com%2FMain%2F583%2F3244776%2F1340778.pdf\" class=\"prnews_a\" rel=\"nofollow noopener noreferrer\">https:\/\/mb.cision.com\/Main\/583\/3244776\/1340778.pdf<\/a><\/span><\/p>\n<\/td>\n<td class=\"prngen3\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">Press release (PDF)<\/span><\/p>\n<\/td>\n<\/tr>\n<\/table>\n<\/div>\n<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO05082&amp;sd=2020-11-27\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/bioinvent-strengthens-investor-relations-301181105.html\">http:\/\/www.prnewswire.com\/news-releases\/bioinvent-strengthens-investor-relations-301181105.html<\/a><\/p>\n<p>SOURCE  BioInvent<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=IO05082&amp;Transmission_Id=202011270408PR_NEWS_USPR_____IO05082&amp;DateId=20201127\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire LUND, Sweden, Nov. 27, 2020 \/PRNewswire\/ &#8212; BioInvent International AB (&#8220;BioInvent&#8221;) (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, announced today the appointment of Cecilia Hofvander as Senior Director Investor Relations, a new position at BioInvent covering external communications and investor relations. She will take office within three months and report directly to CEO Martin Welschof. Cecilia has broad experience within investor relations from positions within publicly listed companies in the biotech industry, including Active Biotech, Abliva and most recently at Alligator Bioscience. She holds a B.Sc in Chemistry and Molecular Biology from Lund University and has completed the Communication Executive Program at the Stockholm School &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bioinvent-strengthens-investor-relations\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BioInvent strengthens Investor Relations&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-388993","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BioInvent strengthens Investor Relations - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bioinvent-strengthens-investor-relations\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioInvent strengthens Investor Relations - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire LUND, Sweden, Nov. 27, 2020 \/PRNewswire\/ &#8212; BioInvent International AB (&#8220;BioInvent&#8221;) (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, announced today the appointment of Cecilia Hofvander as Senior Director Investor Relations, a new position at BioInvent covering external communications and investor relations. She will take office within three months and report directly to CEO Martin Welschof. Cecilia has broad experience within investor relations from positions within publicly listed companies in the biotech industry, including Active Biotech, Abliva and most recently at Alligator Bioscience. She holds a B.Sc in Chemistry and Molecular Biology from Lund University and has completed the Communication Executive Program at the Stockholm School &hellip; Continue reading &quot;BioInvent strengthens Investor Relations&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/bioinvent-strengthens-investor-relations\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-27T12:00:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO05082&amp;sd=2020-11-27\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioinvent-strengthens-investor-relations\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioinvent-strengthens-investor-relations\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BioInvent strengthens Investor Relations\",\"datePublished\":\"2020-11-27T12:00:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioinvent-strengthens-investor-relations\\\/\"},\"wordCount\":555,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioinvent-strengthens-investor-relations\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO05082&amp;sd=2020-11-27\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioinvent-strengthens-investor-relations\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioinvent-strengthens-investor-relations\\\/\",\"name\":\"BioInvent strengthens Investor Relations - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioinvent-strengthens-investor-relations\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioinvent-strengthens-investor-relations\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO05082&amp;sd=2020-11-27\",\"datePublished\":\"2020-11-27T12:00:17+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioinvent-strengthens-investor-relations\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioinvent-strengthens-investor-relations\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioinvent-strengthens-investor-relations\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO05082&amp;sd=2020-11-27\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO05082&amp;sd=2020-11-27\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioinvent-strengthens-investor-relations\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BioInvent strengthens Investor Relations\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BioInvent strengthens Investor Relations - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/bioinvent-strengthens-investor-relations\/","og_locale":"en_US","og_type":"article","og_title":"BioInvent strengthens Investor Relations - Market Newsdesk","og_description":"PR Newswire LUND, Sweden, Nov. 27, 2020 \/PRNewswire\/ &#8212; BioInvent International AB (&#8220;BioInvent&#8221;) (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, announced today the appointment of Cecilia Hofvander as Senior Director Investor Relations, a new position at BioInvent covering external communications and investor relations. She will take office within three months and report directly to CEO Martin Welschof. Cecilia has broad experience within investor relations from positions within publicly listed companies in the biotech industry, including Active Biotech, Abliva and most recently at Alligator Bioscience. She holds a B.Sc in Chemistry and Molecular Biology from Lund University and has completed the Communication Executive Program at the Stockholm School &hellip; Continue reading \"BioInvent strengthens Investor Relations\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/bioinvent-strengthens-investor-relations\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-27T12:00:17+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO05082&amp;sd=2020-11-27","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioinvent-strengthens-investor-relations\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioinvent-strengthens-investor-relations\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BioInvent strengthens Investor Relations","datePublished":"2020-11-27T12:00:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioinvent-strengthens-investor-relations\/"},"wordCount":555,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioinvent-strengthens-investor-relations\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO05082&amp;sd=2020-11-27","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioinvent-strengthens-investor-relations\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/bioinvent-strengthens-investor-relations\/","name":"BioInvent strengthens Investor Relations - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioinvent-strengthens-investor-relations\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioinvent-strengthens-investor-relations\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO05082&amp;sd=2020-11-27","datePublished":"2020-11-27T12:00:17+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioinvent-strengthens-investor-relations\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/bioinvent-strengthens-investor-relations\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioinvent-strengthens-investor-relations\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO05082&amp;sd=2020-11-27","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO05082&amp;sd=2020-11-27"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioinvent-strengthens-investor-relations\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BioInvent strengthens Investor Relations"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/388993","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=388993"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/388993\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=388993"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=388993"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=388993"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}